A Phase IIa Study of Recombinant Human Interleukin-22 IgG2-Fc (F 652) in Combination With Systemic Corticosteroids for the Treatment of Newly Diagnosed Grade II-IV Lower Gastrointestinal Acute Graft-versus-Host Disease (aGVHD) in Hematopoietic Stem Cell Transplantation Recipients (HSCT)
Phase of Trial: Phase I/II
Latest Information Update: 05 May 2017
At a glance
- Drugs F 652 (Primary) ; Prednisone
- Indications Graft-versus-host disease
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Generon (Shanghai) Corporation
- 01 May 2017 Planned End Date changed from 1 Dec 2016 to 1 Jun 2018.
- 01 May 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 01 May 2017 Status changed from not yet recruiting to recruiting.